NAS
SNDX icon

Nykredit A/S’s Syndax Pharmaceuticals SNDX Stock Holding History

Nykredit A/S’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.7K Buy
+3,279
New +$68.2K ﹤0.01% 1418

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Nykredit A/S's SNDX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 3,279 shares worth $71.7K. The stake represents ﹤0.01% of the portfolio and ranks #1418 among its holdings.

155 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Nykredit A/S held 3,279 shares of Syndax Pharmaceuticals worth $71.7K as of Q2 2026.
  • Syndax Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1418 holding.
  • 155 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.